"Lowering prices might encourage more people who might benefit from these medications to start using them." Recently, the IIFH brought together leading scientists, industry innovators and health care experts to examine how GLP-1-based therapies are transforming obesity and diabetes care
Semaglutide, marketed as Wegovy, is recommended by the FDA for weight loss if you meet any of the following criteria: BMI of 27kg/m2 or greater, with at least one weight-related condition (e.g., high blood pressure, Type 2 diabetes, high cholesterol) BMI of 30kg/m2 or greater However, its important to avoid semaglutide if you have a history of: Medullary thyroid cancer Gallbladder disease Pancreatitis Multiple endocrine neoplasia syndrome type 2 (MEN2) Considering semaglutide for weight loss
When gastric emptying is slowed by GLP-1 medications, this gastric distension lasts longer , leading to pressure, bloating, and prolonged fullness
The inflammation reduction cascade Excess body fat is an inflammatory condition
